Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5658003 | 0.98 | GAA (0.66) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL166433 | 0.89 | TDP1 (0.58) | GAALMNAHPGDALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5657522 | 0.87 | GLA (0.58) | GAALMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL2347336 | 0.87 | GAA (0.70) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL13655375 | 0.87 | LMNA (0.84) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL23699040 | 0.84 | GAA (0.62) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL11742767 | 0.84 | LMNA (0.69) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL8762651 | 0.84 | GAA (0.66) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL2691461 | 0.84 | GAA (0.66) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL3903156 | 0.84 | GAA (0.76) | GAALMNAKDM4EHPGDDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | claimed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | claimed |
| EP-0885239-B1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | BATRA SATISH (SE) | 2002-08-07 | — | — | EP | claimed |
| US-5480989-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | claimed |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2023-04-13 | — | — | US | disclosed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| EP-0885239-A1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | Batra, Satish (SE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997027211-A1 | NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS | BATRA SATISH (SE) | 1997-07-31 | — | — | WO | disclosed |
| US-5559120-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5530007-A | ANTITUMOR, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE, IMMUNOSUPPRESSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5508399-A | USEFUL AS IMMUNOSUPPRESSANT, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE AND ANTIUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5480989-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | GAA 1692/4885LMNA 1539/4885KDM4E 3427/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | GAA 1449/4885LMNA 2521/4885KDM4E 4131/4885 |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | GAA 1692/4885LMNA 1539/4885KDM4E 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.